Premium
Engineering temperature‐sensitive poly( N ‐isopropylacrylamide) polymers as carriers of therapeutic proteins
Author(s) -
Uludag Hasan,
Norrie Bryan,
Kousinioris Niki,
Gao Tiejun
Publication year - 2001
Publication title -
biotechnology and bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 189
eISSN - 1097-0290
pISSN - 0006-3592
DOI - 10.1002/bit.1086
Subject(s) - lower critical solution temperature , polymer , poly(n isopropylacrylamide) , phosphate buffered saline , chemistry , polymer chemistry , chromatography , chemical engineering , biophysics , copolymer , organic chemistry , biology , engineering
This study was carried out to engineer N ‐isopropylacrylamide (NiPAM) polymers that contain protein‐reactive N ‐acryloxysuccinimide (NASI) and hydrophobic alkylmethacrylates (AMAs). These thermoreversible, protein‐conjugating polymers hold potential for retention of therapeutic proteins at an application site where tissue regeneration is desired. The lower critical solution temperatures (LCST) of the polymers were effectively controlled by the AMA mole content. The AMAs with longer side‐chains were more effective in lowering the LCST. Polymers without NASI exhibited a stable LCST in phosphate buffer and in serum over a 10‐day study period. The LCST of polymers containing NASI was found to increase over time in phosphate buffer, but not in serum‐containing medium. The LCST increase in phosphate buffer was proportional to the AMA content. The feasibility of localizing a therapeutic protein, recombinant human bone morphogenetic protein‐2 (rhBMP‐2), to a site of application was explored in a rat intramuscular injection model. The results indicated that polymers capable of conjugating to rhBMP‐2 were most effective in localizing the protein irrespective of the LCST (13–25°C). For polymers with no NASI groups, a lower LCST resulted in a better rhBMP‐2 localization. We conclude that thermosensitive polymers can be engineered for delivery of therapeutic proteins to improve their therapeutic efficacy. © 2001 John Wiley & Sons, Inc. Biotechnol Bioeng 73: 510–521, 2001.